Building a European innovation platform for the repurposing of medicinal products

Closed

Programme Category

EU Competitive Programmes

Programme Name

Horizon Europe (2021-2027)

Programme Description

Horizon Europe is the European Union (EU) funding programme for the period 2021 – 2027, which targets the sectors of research and innovation. The programme’s budget is around € 95.5 billion, of which € 5.4 billion is from NextGenerationEU to stimulate recovery and strengthen the EU’s resilience in the future, and € 4.5 billion is additional aid.

Programme Details

Identifier Code

HORIZON-HLTH-2021-DISEASE-04-02

Call

Building a European innovation platform for the repurposing of medicinal products

Summary

Development of therapeutics is a lengthy process that requires a large amount of efforts, time and financial resources. It is often burdened by delays and barriers that account for an average of almost 15 years until a promising candidate molecule becomes an approved medicine. It is therefore of paramount importance to define strategies that facilitate the reduction of timeframes, decrease costs and improve the success rate of this complex and lengthy process.

Detailed Call Description

Proposals should address all of the following:

  • Set up a platform supporting an innovative repurposing model with a harmonized and sustainable dimension in the EU, attracting investments and taking a position of leadership at global level. This model should integrate the scientific, methodological, financial, legal, regulatory, and intellectual property aspects of the repurposing approach.
  • Provide robust and transparent selection mechanisms for prioritising already approved medicinal products or investigational products for repurposing, based on recognized unmet medical needs and sound preliminary data, and identify research priorities for the better understanding of mechanisms of action.
  • Leverage, pool and share existing high quality data assets in the European repurposing landscape, also by using pharmacogenomics, in silico, and artificial intelligence (AI) approaches, innovative preclinical human in vitro cellular/multi-organ validation methods, and deliver new computational tools.
  • Resolve the fragmentation and lack of ownership of the repurposing approach that greatly impedes the efficient exploitation of its potential, networking existing projects and initiatives in the field. Particular attention should be given in supporting and strengthening academic driven research.
  • Devise and test a European innovation platform to enhance the collaboration among relevant European stakeholders, including academia, non-profit organisations, patients, health-care professionals, regulators, health technology assessment bodies, payers, industry, and European Research Infrastructures.

All projects funded under this topic are strongly encouraged to participate in networking and joint activities, as appropriate.  The details of these joint activities will be defined during the grant agreement preparation phase, and the Commission may take on the role of facilitator for networking and exchanges, including with relevant stakeholders, if appropriate.
Ιnternational cooperation is encouraged.

Call Total Budget

€50,00 million

Financing percentage by EU or other bodies / Level of Subsidy or Loan

100%

EU contribution per project: € 25,00 εκατομ.

Thematic Categories

  • Health
  • Research, Technological Development and Innovation

Eligibility for Participation

  • Researchers/Research Centers/Institutions

Call Opening Date

22/06/2021

Call Closing Date

21/09/2021

National Contact Point(s)

Research and Innovation Foundation
Marinos Fotiadis
Contact Phone: 22 205 048
E-mail: mphotiades@research.org.cy
Website: https://www.research.org.cy/

Ioannis Theodorou
Contact Phone: 22 205 038
E-mail: itheodorou@research.org.cy
Website: https://www.research.org.cy/

(Publish Date: 03/08/2021-for internal use only)

EU Contact Point

European Commission, Directorate-General for Research and Innovation

https://ec.europa.eu/info/departments/research-and-innovation_en#contact